Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Gastric Cancer

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 63 articles:
HTML format



Single Articles


    February 2024
  1. RUGGE M, Genta RM, Malfertheiner P, Dinis-Ribeiro M, et al
    RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates.
    Gut. 2024;73:407-441.
    PubMed     Abstract available


    January 2024
  2. TAKEUCHI C, Yamashita S, Liu YY, Takeshima H, et al
    Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation.
    Gut. 2024;73:255-267.
    PubMed     Abstract available


    December 2023
  3. LATORRE G, Silva F, Montero I, Bustamante M, et al
    Comparison of OLGA and OLGIM as predictors of gastric cancer in a Latin American population: the ECHOS Study.
    Gut. 2023 Dec 26:gutjnl-2023-331059. doi: 10.1136/gutjnl-2023-331059.
    PubMed    


  4. MORAIS R, Libanio D, Dinis Ribeiro M, Ferreira A, et al
    Predicting residual neoplasia after a non-curative gastric ESD: validation and modification of the eCura system in the Western setting: the W-eCura score.
    Gut. 2023;73:105-117.
    PubMed     Abstract available


  5. TAN P, Chu Y
    Single-cell profiling of gastric cardia adenocarcinoma reveals drivers of cancer stemness and therapeutic targets.
    Gut. 2023;73:1-2.
    PubMed    


  6. WANG Z, Wang Q, Chen C, Zhao X, et al
    NNMT enriches for AQP5(+) cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma.
    Gut. 2023;73:63-77.
    PubMed     Abstract available


    November 2023
  7. LAHNER E, Dilaghi E, Dottori L, Annibale B, et al
    Not all that is corpus restricted is necessarily autoimmune.
    Gut. 2023;72:2384-2385.
    PubMed    


    August 2023
  8. LEJA M
    Potential of personalised approaches in gastric cancer prevention.
    Gut. 2023 Aug 27:gutjnl-2023-330215. doi: 10.1136/gutjnl-2023-330215.
    PubMed    


    July 2023
  9. XU Z, Huang Y, Hu C, Du L, et al
    Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study.
    Gut. 2023 Jul 17:gutjnl-2023-330045. doi: 10.1136/gutjnl-2023-330045.
    PubMed     Abstract available


  10. CAO LL, Lu H, Soutto M, Bhat N, et al
    Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-gamma signalling.
    Gut. 2023 Jul 4:gutjnl-2022-329134. doi: 10.1136/gutjnl-2022-329134.
    PubMed     Abstract available


    May 2023
  11. LEI WY, Lee JY, Chuang SL, Bair MJ, et al
    Eradicating Helicobacter pylori via (13)C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method.
    Gut. 2023 May 17:gutjnl-2023-329871. doi: 10.1136/gutjnl-2023-329871.
    PubMed     Abstract available


    April 2023
  12. RALSER A, Dietl A, Jarosch S, Engelsberger V, et al
    Helicobacter pylori promotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature.
    Gut. 2023 Apr 4:gutjnl-2022-328075. doi: 10.1136/gutjnl-2022-328075.
    PubMed     Abstract available


  13. FAN Y, Li Y, Yao X, Jin J, et al
    Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment.
    Gut. 2023;72:624-637.
    PubMed     Abstract available


    March 2023
  14. XU C, Huang KK, Law JH, Chua JS, et al
    Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.
    Gut. 2023 Mar 14:gutjnl-2022-328332. doi: 10.1136/gutjnl-2022-328332.
    PubMed     Abstract available


    February 2023
  15. RUGGE M, Genta RM, Malfertheiner P, Graham DY, et al
    Gastric cancer risk in autoimmune gastritis: evidence versus opinion.
    Gut. 2023 Feb 27:gutjnl-2023-329618. doi: 10.1136/gutjnl-2023-329618.
    PubMed    


    January 2023
  16. WALDUM HL
    Conclusion that autoimmune gastritis does not predispose to gastric cancer is unproven.
    Gut. 2023 Jan 24:gutjnl-2022-329323. doi: 10.1136/gutjnl-2022-329323.
    PubMed    


  17. GOLDENRING J
    No H. pylori, no adenocarcinoma for patients with autoimmune gastritis.
    Gut. 2023;72:1-2.
    PubMed    


    October 2022
  18. LI M, Park JY, Sheikh M, Kayamba V, et al
    Population-based investigation of common and deviating patterns of gastric cancer and oesophageal cancer incidence across populations and time.
    Gut. 2022 Oct 14. pii: gutjnl-2022-328233. doi: 10.1136/gutjnl-2022-328233.
    PubMed     Abstract available


    September 2022
  19. RUGGE M, Genta RM, Malfertheiner P, Graham DY, et al
    Steps forward in understanding gastric cancer risk.
    Gut. 2022 Sep 16. pii: gutjnl-2022-328514. doi: 10.1136/gutjnl-2022-328514.
    PubMed    


    August 2022
  20. LENTI MV, Broglio G, Di Sabatino A
    Unravelling the risk of developing gastric cancer in autoimmune gastritis.
    Gut. 2022 Aug 18. pii: gutjnl-2022-328345. doi: 10.1136/gutjnl-2022-328345.
    PubMed    


  21. DAWSON RE, Deswaerte V, West AC, Tang K, et al
    STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis.
    Gut. 2022;71:1515-1531.
    PubMed     Abstract available


    July 2022
  22. WANG Z, Han W, Xue F, Zhao Y, et al
    Nationwide gastric cancer prevention in China, 2021-2035: a decision analysis on effect, affordability and cost-effectiveness optimisation.
    Gut. 2022 Jul 28. pii: gutjnl-2021-325948. doi: 10.1136/gutjnl-2021-325948.
    PubMed     Abstract available


  23. HO SWT, Sheng T, Xing M, Ooi WF, et al
    Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities.
    Gut. 2022 Jul 11. pii: gutjnl-2021-326483. doi: 10.1136/gutjnl-2021-326483.
    PubMed     Abstract available


  24. BROWN JW
    Gut check: can other microbes or communities phenocopy H. pylori's early gastric pathology?
    Gut. 2022;71:1241-1242.
    PubMed    


  25. SUNDAR R, Huang KK, Kumar V, Ramnarayanan K, et al
    Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
    Gut. 2022;71:1277-1288.
    PubMed     Abstract available


  26. KWON SK, Park JC, Kim KH, Yoon J, et al
    Human gastric microbiota transplantation recapitulates premalignant lesions in germ-free mice.
    Gut. 2022;71:1266-1276.
    PubMed     Abstract available


    June 2022
  27. RUGGE M, Bricca L, Guzzinati S, Sacchi D, et al
    Autoimmune gastritis: long-term natural history in naive Helicobacter pylori-negative patients.
    Gut. 2022 Jun 30. pii: gutjnl-2022-327827. doi: 10.1136/gutjnl-2022-327827.
    PubMed     Abstract available


  28. TONG Y, Cheng PSW, Or CS, Yue SSK, et al
    Escape from cell-cell and cell-matrix adhesion dependence underscores disease progression in gastric cancer organoid models.
    Gut. 2022 Jun 15. pii: gutjnl-2022-327121. doi: 10.1136/gutjnl-2022-327121.
    PubMed     Abstract available


  29. CALDWELL B, Meyer AR, Weis JA, Engevik AC, et al
    Chief cell plasticity is the origin of metaplasia following acute injury in the stomach mucosa.
    Gut. 2022;71:1068-1077.
    PubMed     Abstract available


    April 2022
  30. QUANTE M, Wang TC, Bass AJ
    Adenocarcinoma of the oesophagus: is it gastric cancer?
    Gut. 2022 Apr 1. pii: gutjnl-2022-327096. doi: 10.1136/gutjnl-2022-327096.
    PubMed    


    March 2022
  31. DONG X, Song S, Li Y, Fan Y, et al
    Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency.
    Gut. 2022;71:467-478.
    PubMed     Abstract available


    December 2021
  32. SONG S, Chen Q, Li Y, Lei G, et al
    Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma.
    Gut. 2021;70:2238-2248.
    PubMed     Abstract available


    November 2021
  33. ZENG R, Sha W, Wang J, Zhuo Z, et al
    Evaluation of proton pump inhibitors and risks of gastric cancer.
    Gut. 2021 Nov 26. pii: gutjnl-2021-326291. doi: 10.1136/gutjnl-2021-326291.
    PubMed    


  34. ARNOLD M, Morgan E, Bardot A, Rutherford MJ, et al
    International variation in oesophageal and gastric cancer survival 2012-2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study).
    Gut. 2021 Nov 25. pii: gutjnl-2021-325266. doi: 10.1136/gutjnl-2021-325266.
    PubMed     Abstract available


  35. LIU X, Chen T, Cheng J, Gao P, et al
    Endoscopic transmural route for dissection of gastric submucosal tumors with extraluminal growth: experience in two cases.
    Gut. 2021;70:2052-2054.
    PubMed    


  36. HAO D, He S, Harada K, Pizzi MP, et al
    Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma.
    Gut. 2021;70:2055-2065.
    PubMed     Abstract available


    October 2021
  37. MATSUO J, Douchi D, Myint K, Mon NN, et al
    Iqgap3-Ras axis drives stem cell proliferation in the stomach corpus during homoeostasis and repair.
    Gut. 2021;70:1833-1846.
    PubMed     Abstract available


    September 2021
  38. RINKE A, Auernhammer CJ, Bodei L, Kidd M, et al
    Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?
    Gut. 2021;70:1768-1781.
    PubMed     Abstract available


  39. SMYTH EC, Vlachogiannis G, Hedayat S, Harbery A, et al
    EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
    Gut. 2021;70:1632-1641.
    PubMed     Abstract available


    August 2021
  40. ARAI J, Niikura R, Hayakawa Y, Aoki T, et al
    OLGIM staging and proton pump inhibitor use predict the risk of gastric cancer.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325551. doi: 10.1136/gutjnl-2021-325551.
    PubMed    


    July 2021
  41. PATEL J, Berezowski I, Janapala RN, Pourmand A, et al
    Proton pump inhibitors and gastric cancer: a population-based cohort study.
    Gut. 2021 Jul 14. pii: gutjnl-2021-325385. doi: 10.1136/gutjnl-2021-325385.
    PubMed    


  42. ABRAHAMI D, McDonald EG, Schnitzer ME, Barkun AN, et al
    Proton pump inhibitors and risk of gastric cancer: population-based cohort study.
    Gut. 2021 Jul 5. pii: gutjnl-2021-325097. doi: 10.1136/gutjnl-2021-325097.
    PubMed     Abstract available


  43. YAMAO K, Kitano M, Chiba Y, Ogura T, et al
    Endoscopic placement of covered versus uncovered self-expandable metal stents for palliation of malignant gastric outlet obstruction.
    Gut. 2021;70:1244-1252.
    PubMed     Abstract available


    May 2021
  44. SUNDAR R, Barr Kumarakulasinghe N, Huak Chan Y, Yoshida K, et al
    Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.
    Gut. 2021 May 12. pii: gutjnl-2021-324060. doi: 10.1136/gutjnl-2021-324060.
    PubMed     Abstract available


  45. SEO SI, Park CH, You SC, Kim JY, et al
    Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
    Gut. 2021 May 11. pii: gutjnl-2020-323845. doi: 10.1136/gutjnl-2020-323845.
    PubMed     Abstract available


  46. LEE JWJ, Zhu F, Srivastava S, Tsao SK, et al
    Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP).
    Gut. 2021 May 11. pii: gutjnl-2021-324057. doi: 10.1136/gutjnl-2021-324057.
    PubMed     Abstract available


    March 2021
  47. LO CH, Kwon S, Wang L, Polychronidis G, et al
    Periodontal disease, tooth loss, and risk of oesophageal and gastric adenocarcinoma: a prospective study.
    Gut. 2021;70:620-621.
    PubMed    


  48. ZHANG M, Hu S, Min M, Ni Y, et al
    Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing.
    Gut. 2021;70:464-475.
    PubMed     Abstract available


    February 2021
  49. BEALES ILP
    Gastric biopsies in the assessment and management of patients at risk of gastric adenocarcinoma.
    Gut. 2021;70:431-432.
    PubMed    


  50. CHEN R, Liu Y, Song G, Li B, et al
    Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study.
    Gut. 2021;70:251-260.
    PubMed     Abstract available


  51. TAKENAKA K, Kimura M, Ohtsuka K
    Colonic strictures mimicking Crohn's disease.
    Gut. 2021;70:233-387.
    PubMed    


    January 2021
  52. AJANI JA, Xu Y, Huo L, Wang R, et al
    YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition.
    Gut. 2021;70:55-66.
    PubMed     Abstract available


    November 2020
  53. SUNDAR R, Liu DH, Hutchins GG, Slaney HL, et al
    Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination.
    Gut. 2020 Nov 23. pii: gutjnl-2020-320805. doi: 10.1136/gutjnl-2020-320805.
    PubMed     Abstract available


    October 2020
  54. SO JBY, Kapoor R, Zhu F, Koh C, et al
    Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population.
    Gut. 2020 Oct 7. pii: gutjnl-2020-322065. doi: 10.1136/gutjnl-2020-322065.
    PubMed     Abstract available


  55. LIOU JM, Malfertheiner P, Lee YC, Sheu BS, et al
    Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus.
    Gut. 2020 Oct 1. pii: gutjnl-2020-322368. doi: 10.1136/gutjnl-2020-322368.
    PubMed     Abstract available


  56. MARCOS P, Brito-Goncalves G, Libanio D, Pita I, et al
    Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West?
    Gut. 2020;69:1762-1768.
    PubMed     Abstract available


  57. KRISHNAN V, Lim DXE, Hoang PM, Srivastava S, et al
    DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia.
    Gut. 2020;69:1738-1749.
    PubMed     Abstract available


    September 2020
  58. BANKS M, Uedo N, Bhandari P, Gotoda T, et al
    EMR achieves similar oncological outcomes as ESD for gastric neoplasia of <1cm, requiring less expertise, training and time.
    Gut. 2020;69:1.
    PubMed    


  59. SHAHIDI N, Bourke MJ
    ESD, not EMR, should be the first-line therapy for early gastric neoplasia.
    Gut. 2020;69:1-2.
    PubMed    


  60. GHISA M, Rugge M, Fassan M, Farinati F, et al
    There is much more to rely on histology than the sole endoscopy tells us.
    Gut. 2020;69:1.
    PubMed    


    June 2020
  61. OOI WF, Nargund AM, Lim KJ, Zhang S, et al
    Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma.
    Gut. 2020;69:1039-1052.
    PubMed     Abstract available


    April 2020
  62. XIONG J, Wang Y, Chen G, Jin L, et al
    Proton pump inhibitors and the risk of gallbladder cancer: a hospital-based case-control study.
    Gut. 2020 Apr 9. pii: gutjnl-2020-321052. doi: 10.1136/gutjnl-2020-321052.
    PubMed    


    May 2019
  63. DOORAKKERS E, Lagergren J, Engstrand L, Brusselaers N, et al
    Reply to: Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a western population.
    Gut. 2019 May 21. pii: gutjnl-2019-319000. doi: 10.1136/gutjnl-2019-319000.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Gastric Cancer is free of charge.